These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Comparison of valporic acid efficacy in familial versus sporadic cases of juvenile myoclonic epilepsy. Motamedi M; Mohammad Ali S; Rahmat M Neurol India; 2006 Jun; 54(2):186-9; discussion 189. PubMed ID: 16804266 [TBL] [Abstract][Full Text] [Related]
12. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. Park KM; Kim SH; Nho SK; Shin KJ; Park J; Ha SY; Kim SE J Clin Neurosci; 2013 Aug; 20(8):1079-82. PubMed ID: 23673144 [TBL] [Abstract][Full Text] [Related]
13. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India. Mehndiratta MM; Aggarwal P Seizure; 2002 Oct; 11(7):431-6. PubMed ID: 12237068 [TBL] [Abstract][Full Text] [Related]
14. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Calleja S; Salas-Puig J; Ribacoba R; Lahoz CH Seizure; 2001 Sep; 10(6):424-7. PubMed ID: 11700996 [TBL] [Abstract][Full Text] [Related]
15. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). Asadi-Pooya AA; Hashemzehi Z; Emami M Seizure; 2014 Nov; 23(10):889-91. PubMed ID: 25189101 [TBL] [Abstract][Full Text] [Related]
16. Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors. Senf P; Schmitz B; Holtkamp M; Janz D Neurology; 2013 Dec; 81(24):2128-33. PubMed ID: 24212391 [TBL] [Abstract][Full Text] [Related]